Stocktoria
Xenetic Biosciences, Inc. XBIO
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2016-11-07
Xenetic Biosciences, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $3.0M | $2.5M | $2.5M | $1.7M | $1.2M |
| R&D expense | $3.1M | $3.3M | $3.5M | $4.8M | $3.2M |
| Operating income | -$2.8M | -$4.2M | -$4.5M | -$6.7M | -$5.7M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$2.7M | -$4.0M | -$4.1M | -$6.6M | -$5.6M |
| EPS (diluted) | $-1.58 | $-2.57 | $-2.71 | $-4.61 | $-0.55 |
| Operating cash flow | -$2.3M | -$2.8M | -$4.1M | -$4.6M | -$4.7M |
| Total assets | $8.4M | $6.9M | $10.6M | $14.7M | $19.8M |
| Total liabilities | $968,025 | $894,263 | $809,585 | $1.1M | $1.4M |
| Shareholders' equity | $7.4M | $6.0M | $9.8M | $13.6M | $18.4M |
Source: SEC EDGAR filings · CIK 0001534525 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.